Karyopharm Therapeutics (KPTI) Tops Q2 EPS by 1c; Offers FY22 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. ETSY

Go back to Karyopharm Therapeutics (KPTI) Tops Q2 EPS by 1c; Offers FY22 Revenue Guidance

Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

August 4, 2022 7:30 AM EDT

Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021;

XPOVIO® (selinexor) Net Product Revenue of $29.0 Million, a 44% Increase Over Q2 2021

 Received  Full Marketing Authorization from the European Commission Expanding Indication for NEXPOVIO® (selinexor) for Treatment of Adults with Multiple Myeloma Who Have Received at Least One Prior Therapy

Clinical Updates from Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis and Interim Data from Phase 2 Study Evaluating Eltanexor in Relapsed/Refractory MDS Expected in 2H 2022

Company Provides... More